Philochem and RayzeBio, a subsidiary of Bristol-Myers Squibb, have announced a definitive agreement under which RayzeBio will purchase the exclusive worldwide rights to prostate cancer therapeutic OncoACP3.  OncoACP3 is a small molecule ligand with high affinity and specificity for Acid Phosphatase 3 (ACP3), a novel target in prostate cancer.   The compound is currently under evaluation […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!